Article Information
PubMed
History
- Published online September 27, 2004.
Copyright & Usage
© 2004 Canadian Medical Association or its licensors
Author Information
- Karin H. Humphries,
- Charles R. Kerr,
- Michael Steinbuch,
- Paul Dorian,
- for The Canadian Registry of Atrial Fibrillation (CARAF) Investigators
- From the Department of Medicine, University of British Columbia (Humphries, Kerr); the Centre for Health Evaluation & Outcomes Sciences (Humphries), Vancouver, BC; Health Care Research Center, Procter and Gamble Pharmaceuticals Inc., Mason, Ohio (Steinbuch); and the Department of Medicine, University of Toronto, Toronto, Ont. (Dorian)Canadian Registry of Atrial Fibrillation (CARAF) Investigators: Charles R. Kerr, St. Paul's Hospital and the University of British Columbia, Vancouver, BC; Robert Sheldon, University of Calgary, Calgary, Alta.; George Klein, University of Western Ontario, London, Ont.; Stuart Connolly, Hamilton General Hospital, Hamilton, Ont.; Martin Green, Ottawa Heart Institute, Ottawa, Ont.; Mario Talajic, Montreal Heart Institute, Montréal, Que.; Paul Dorian, St. Michael's Hospital, and the University of Toronto, Toronto, Ont.; David Newman, St. Michael's Hospital and the University of Toronto, Toronto Ont.
Statistics from Altmetric.com
Cited By...
In this issue
Article tools
Respond to this article
Jump to section
Related Articles
Cited By...
- Docosahexaenoic Acid, but Not Eicosapentaenoic Acid, Supplementation Reduces Vulnerability to Atrial Fibrillation
- Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic
- Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?
More in this TOC Section
Similar Articles
Collections
